Adjuvant therapy with EGFR TKI, and particularly Osimertinib, is currently under investigation in clinical trials to improve survival and prevent metastatic evolution in EGFR-mutated locally unresectable stage III NSCLC patients treated by chemoradiotherapy [41]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.